The Epidemiology, Evolution, and Treatment of KPC-Producing Organisms

被引:0
作者
Ann Marie Porreca
Kaede V. Sullivan
Jason C. Gallagher
机构
[1] Temple University School of Pharmacy,
[2] Lewis Katz School of Medicine at Temple University,undefined
来源
Current Infectious Disease Reports | 2018年 / 20卷
关键词
Carbapenemases; KPC; Multi-drug resistance; KPC treatment; KPC infections; KPC epidemiology;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 396 条
[1]  
Ben-David D(2017)Outcome of carbapenem resistant Clin Microbiol Infect 18 54-60
[2]  
Kordevani R(2008) bloodstream infections Infect Control Hosp Epidemiol 29 1099-1106
[3]  
Keller N(2015)Outcomes of carbapenem-resistant Antimicrob Agents Chemother 59 5873-5884
[4]  
Tai I(2017) infection and the impact of antimicrobial and adjunctive therapies Sci Rep 7 1-11
[5]  
Marzel O(2008)Carbapenemase-producing Argentina Emerg Infect Diseas 14 1178-1180
[6]  
Gal-Mor Y(2006), a key pathogen set for global nosocomial dominance Diagn Microbiol Infect Dis 56 367-372
[7]  
Patel G(2009)Genomic epidemiology of global Antimicrob Agents Chemother 53 3599-3601
[8]  
Huprikar S(2001) carbapenemase (KPC)-producing Antimicrob Agents Chemother 45 1151-1161
[9]  
Factor SH(2003)Klebsiella pneumoniae carbapenemase-2, Buenos Aires Antimicrob Agents Chemother 47 1297-1300
[10]  
Jenkins SG(2003)Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States medical centers: report from the MYSTIC program (1999-2005) J Antimicrob Chemother 51 711-714